BioSpace News Archive

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis

Cancels Upcoming Third Quarter Conference Call in Light of Pending Transaction with Siemens Healthineers

Legend Biotech Corporation, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced that its Board of Directors has appointed Dr. Frank Zhang to serve as Chief Executive Officer, effective immediately.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites

Innovent Biologics, Inc. announced that the first patient has been successfully dosed in a Phase 1 clinical trial of the potentially first-in-class recombinant anti-CD47/PD-L1 bispecific antibody in China.

Brings Together Highly Complementary Portfolios to Empower Clinicians and Patients in the Fight Against Cancer

For the six months ended June 30, 2020, Legend Biotech expects to record a loss from approximately US$89.0 million to US$103.0 million from continuous operations, changes of fair value of such Series A Preferred Shares, and listing expenses), including research and development expenses of approximately US$96.5 million to US$111.8 million.

Qualigen Therapeutics, Inc., announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $10,000,000 of 1,717,106 Common Shares and 1,287,829 Common Warrants at a combined purchase price of $5.82375 in a registered direct offering priced at-the-market under Nasdaq rules.

VistaGen Therapeutics, Inc., a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system disorders, announced the pricing of its underwritten public offering of 15,625,000 shares of its common stock at a public offering price of $0.80 per share.